Sermorelin
Evidence: B/C — Meaningful Human EvidenceGH Axis / Body Composition
Evidence Snapshot
Regulatory Context
Historical U.S. products contained sermorelin acetate. Geref Diagnostic (NDA 19-863; approved December 28, 1990) was used to evaluate pituitary growth-hormone secretory capacity. Geref Pediatric (NDA 20-443; approved September 26, 1997) was indicated for idiopathic growth-hormone deficiency in children with growth failure. FDA withdrew approval of both NDAs effective June 18, 2009 after sponsor discontinuation and later determined that the products were not withdrawn for reasons of safety or effectiveness. No FDA-approved sermorelin product is currently marketed in the United States.
Research Takeaway
Sermorelin is growth hormone-releasing hormone 1-29 amide, GHRH(1-29)-NH2/GRF(1-29)-NH2; sermorelin acetate is its acetate-salt drug-substance form.
See all 12 evidence claims →Quick Summary
Sermorelin is the amidated 1–29 fragment of human growth hormone–releasing hormone. Historical human studies and former U.S. approvals support its ability to stimulate pituitary growth-hormone release and, in selected pediatric growth-hormone-deficiency populations, promote growth. Evidence for modern adult wellness, anti-aging, recovery, or body-composition uses remains limited and should not be inferred from the former pediatric and diagnostic indications.
Mechanism & Research Overview
Sermorelin is the amidated 1–29 fragment of human growth hormone–releasing hormone and acts as an agonist at growth hormone–releasing hormone receptors on anterior-pituitary somatotrophs. The human GHRH receptor is a secretin-family G-protein-coupled receptor; receptor activation increases intracellular cAMP and stimulates secretion of endogenous growth hormone. Sermorelin therefore acts upstream of growth hormone itself and should not be described as recombinant growth hormone or as a direct growth-hormone-receptor agonist.
Read more about the mechanism
Its plasma exposure is brief, but the downstream growth-hormone response lasts longer than the peptide remains in circulation. Official Geref product information reported an intravenous plasma half-life of 6–7 minutes, a peak growth-hormone response at about 30 minutes, and a response lasting approximately 2–3 hours. In a randomized study of 30 healthy men, intravenous GHRH(1–29)-NH2 was rapidly eliminated while growth hormone remained elevated for about 3 hours; intranasal bioavailability was only 3–5%, demonstrating that administration route materially changes systemic exposure.
Rapid clearance is consistent with enzymatic degradation of GHRH-family peptides in plasma, principally by dipeptidyl peptidase IV cleavage near the amino terminus and, to a lesser extent, by trypsin-like enzymes. The magnitude of growth-hormone release also depends on functioning pituitary somatotrophs and physiologic context. Somatostatin tone, obesity, hyperglycemia, elevated circulating free fatty acids, untreated hypothyroidism, and drugs that alter pituitary growth-hormone secretion can blunt or otherwise change the response. An acute rise in growth hormone does not by itself establish sustained IGF-1 elevation or clinical benefits for fat loss, muscle gain, sleep, recovery, longevity, or anti-aging.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Sermorelin is growth hormone-releasing hormone 1-29 amide, GHRH(1-29)-NH2/GRF(1-29)-NH2; sermorelin acetate is its acetate-salt drug-substance form.
Sources: Growth hormone-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency; Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone; Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Supported
GEREF (sermorelin acetate) historically had FDA-approved diagnostic and pediatric growth-hormone-deficiency products, including a 1997 treatment approval for children with growth failure due to growth hormone deficiency.
Sources: Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness; FDA Orphan Drug Designations and Approvals — Sermorelin acetate / Geref
Supported
FDA later determined that the discontinued GEREF products were not withdrawn from sale for reasons of safety or effectiveness.
Supported
A historical multicenter study reported accelerated growth during one year of once-daily GHRH(1-29)-NH2 therapy in children with growth hormone deficiency.
Supported
Evidence for anti-aging, recovery, and body-composition benefits in healthy adults remains limited.
Supported
Modern compounded sermorelin preparations should not be represented as the historical FDA-approved GEREF products unless product-specific approval and equivalence are independently established.
Sources: Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness; FDA Orphan Drug Designations and Approvals — Sermorelin acetate / Geref
Supported
FDA withdrew approval of the GEREF NDAs effective June 18, 2009 after the sponsor discontinued the products and requested withdrawal.
Supported
Historical pediatric clinical studies show that GHRH(1-29)-NH2 can stimulate growth in children with hypothalamic growth hormone deficiency or idiopathic short stature; these are historical pediatric endocrine findings and do not establish equivalence for current compounded adult-wellness products.
Sources: Growth hormone-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency; Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone; Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group; Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity
Supported
In a randomized pediatric comparison, higher-dose GHRH(1-29)-NH2 increased height velocity, while recombinant growth hormone remained superior on at least one bone-age-adjusted height outcome.
Sources: Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone
Supported
GHRH(1-29) administration increased GH and IGF-1 levels in older men in a human endocrine-physiology study.
Supported
Sermorelin must not be conflated with CJC-1295, CJC-1295 with DAC, CJC-1295 without DAC, marketplace 'Modified GRF(1-29)', tesamorelin, or full-length native GHRH.
Sources: Growth hormone-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency; Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Supported
A human pharmacokinetic/pharmacodynamic study in healthy adult men compared intravenous and intranasal GHRH(1-29)-NH2 administration and reported route-dependent growth-hormone response.
Does not establish
Evidence boundary: This is administration-route pharmacokinetic and endocrine-response evidence in healthy adults, not evidence of therapeutic anti-aging or body-composition efficacy.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Historical FDA review and clinical literature reported transient injection-site pain, redness or swelling, facial flushing, headache, nausea, vomiting, altered taste, chest tightness and related short-lived reactions.Safety Consideration
Historical pediatric exposure was associated with anti-sermorelin antibodies in some patients; FDA reviewers reported that these were not clearly linked to generalized allergic reactions or reduced efficacy, but immunogenicity remains relevant for peptide products.Safety Consideration
Current compounded preparations do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality.Safety Consideration
Small studies showed endocrine and body-composition changes, but do not establish broad anti-aging, recovery, sleep, or longevity benefits in healthy adults.Safety Consideration
Sustained or excessive activation of the GH/IGF-1 axis may be clinically relevant for glucose metabolism, edema-related symptoms, sleep apnea, proliferative disorders, or other conditions; long-term safety for contemporary compounded use is not established.
Research Areas Being Studied
Human research includes GH-stimulation testing, pediatric growth-hormone deficiency, and small studies of age-related GH-axis changes. Those settings do not establish effectiveness for modern adult wellness uses.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women (1997):
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group (1996):
- Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity (1994):
- Growth hormone-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency (1993):
- Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone (1993):
- Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration (1993):
- Growth hormone-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men (1992):
- The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships (1986):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women | 1997 | 19 adults (10 women, 9 men), ages 55-71, placebo-controlled | Activated the somatotropic axis in both sexes; men gained lean mass (+1.26kg) and improved insulin sensitivity, libido, and well-being; women showed minimal metabolic gains beyond increased skin thickness. Only adverse effect was transient elevated cholesterol.
| ||
| Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group | 1996 | Children with growth-hormone deficiency | The trial reported accelerated growth during the first year in children with GH deficiency.
| Use the original publication and historical FDA labeling for detailed adverse-event interpretation. | |
| Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity | 1994 | Children with idiopathic short stature | Sermorelin (GHRH(1-29)-NH2) treatment produced a sustained increase in growth velocity in children with idiopathic short stature. | Historical pediatric idiopathic-short-stature population; distinct from modern adult wellness/anti-aging use and must not be generalized to it. | |
| Growth hormone-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency | 1993 | In children with hypothalamic growth hormone deficiency, GHRH(1-29)-NH2 treatment stimulated growth, providing direct historical human therapeutic evidence. | |||
| Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone | 1993 | In prepubertal children with hypothalamic GHD, higher-dose GHRH(1-29)-NH2 increased height velocity comparably to GH on some measures, although GH was superior on at least one bone-age-adjusted height measure. | |||
| Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration | 1993 | Healthy subjects | Characterized pharmacokinetics of GHRH(1-29)-NH2 and GH-secretion response after intravenous versus intranasal administration in healthy subjects. | Route-of-administration pharmacokinetic study in healthy subjects; does not establish therapeutic efficacy for any indication. | |
| Growth hormone-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men | 1992 | Repeated GHRH(1-29) administration increased GH and IGF-1 levels in older men, demonstrating endocrine activity but not establishing anti-aging, body-composition, or longevity efficacy. | |||
| The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships | 1986 | Normal adult men | The 29-amino-acid analog stimulated GH release by all three routes, with the strongest response after intravenous administration and weaker exposure-response by subcutaneous and intranasal routes.
| The abstract reported no adverse effect in this small acute study; this does not establish long-term safety. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| 2026 World Anti-Doping Agency Prohibited List | 2026 | Anti-doping regulatory standard | WADA lists growth-hormone-releasing factors and secretagogues, including CJC-1295, sermorelin, GHRP-2, GHRP-6, and examorelin/hexarelin, as prohibited in sport. | Anti-doping status is not a clinical safety or efficacy determination. | |
| Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | 2013 | FDA regulatory determination | Geref was approved as a diagnostic agent (NDA 019863, ~1990) and later a pediatric GHD therapeutic (NDA 020443, 1997); the manufacturer voluntarily discontinued it in 2008 for commercial/supply reasons, and the FDA formally withdrew marketing approval effective June 18, 2009. FDA's later determination confirmed the withdrawal was not for safety or effectiveness reasons. | This determination does not mean the products remain approved and marketed, and it does not establish safety for modern compounded adult-wellness use. | |
| FDA EGRIFTA (NDA 022505) Medical Review — Historical Discussion of Geref Diagnostic and Pediatric Use (Not a Geref NDA Approval File) | 2010 | FDA review of historical regulatory and safety information | FDA reviewers summarized former diagnostic and pediatric indications, discontinuation, common transient reactions, and anti-Geref antibody observations.
| Historical safety findings were indication-, population-, dose-, and route-specific and cannot be extrapolated to contemporary compounded adult use. | |
| FDA Orphan Drug Designations and Approvals — Sermorelin acetate / Geref | 1997 | FDA records Geref (sermorelin acetate) as approved on September 26, 1997 for the designated pediatric growth-hormone-deficiency context. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? | 2006 | Editorial/perspective piece on adult-onset GH insufficiency management | Perspective piece discussing sermorelin's potential role in adult-onset GH insufficiency; editorial format with no underlying data table independently extracted. | ||
| Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency | 1999 | Review of pediatric GHD diagnostic and therapeutic use | Sustained height-velocity increase in GH-deficient children, though inferior to direct somatropin therapy; well tolerated, main adverse effects were facial flushing and injection-site pain. Also reviewed diagnostic use, noting fewer false positives than other provocative GH tests.
|
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational research summary only. This page does not provide medical advice, treatment guidance, product-quality assurance, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-07-12.
Follow research updates for Sermorelin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.